910386-57-1 Usage
General Description
2-(3-bromopyridin-2-yl)ethanamine is a chemical compound classified as an amine. It consists of a pyridine ring with a bromine atom at the 3-position and an ethylamine group attached to the 2-position. 2-(3-bromopyridin-2-yl)ethanamine is commonly used in the field of organic synthesis as a building block for the construction of more complex organic molecules. It can also be utilized in pharmaceutical research and development, as well as in the production of agrochemicals and other industrial applications. Additionally, it may have potential biological activity and could be used as a precursor for the synthesis of various bioactive compounds. Overall, 2-(3-bromopyridin-2-yl)ethanamine is an important chemical with various potential applications in different scientific and industrial fields.
Check Digit Verification of cas no
The CAS Registry Mumber 910386-57-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,0,3,8 and 6 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 910386-57:
(8*9)+(7*1)+(6*0)+(5*3)+(4*8)+(3*6)+(2*5)+(1*7)=161
161 % 10 = 1
So 910386-57-1 is a valid CAS Registry Number.
910386-57-1Relevant articles and documents
Phenethyl nicotinamides, a novel class of NaV1.7 channel blockers: Structure and activity relationship
Kers, Inger,MacSari, Istvan,Csjernyik, Gabor,Nyloef, Martin,Skogholm, Karin,Sandberg, Lars,Minidis, Alexander,Bueters, Tjerk,Malmborg, Jonas,Eriksson, Anders B.,Lund, Per-Eric,Venyike, Elisabet,Luo, Lei,Nystroem, Jan-Erik,Besidski, Yevgeni
, p. 6108 - 6115 (2012/10/30)
The NaV1.7 ion channel is an attractive target for development of potential analgesic drugs based on strong genetic links between mutations in the gene coding for the channel protein and inheritable pain conditions. The (S)-N-chroman-3-ylcarboxamide series, exemplified by 1, was used as a starting point for development of new channel blockers, resulting in the phenethyl nicotinamide series. The structure and activity relationship for this series was established and the metabolic issues of early analogues were addressed by appropriate substitutions. Compound 33 displayed acceptable overall in vitro properties and in vivo rat PK profile.
